tbuckley/cabot-search huggingface dataset:
Abstract P292: The Economic Burden To Medicare Of Stroke Events In Atrial Fibrillation Populations With And Without Treatment
Authors: Aarti A Patel, Kristine Ogden, Mark Veerman, Samir Mody, Winnie W Nelson, Nancy Neil
Journal: Circulation (2012)

Purpose: About 2.3 million in the US have atrial fibrillation (AF), a diagnosis which confers a 5-fold increased stroke risk. Prevention is paramount as AF-related strokes are often severe. Anticoagulation reduces the annual incidence of stroke in AF patients by 30–40%. However, anticoagulation is prescribed for only about half of appropriate AF patients. More strokes may be prevented with wider use of anticoagulation therapy. This study estimates the economic burden to Medicare of stroke events in AF cohorts, and the estimated economic implications of stroke reduction associated with increased anticoagulant prophylaxis among moderate to high risk stroke patients. Methods: We used a microcosting model to estimate the annual economic burden of ischemic and hemorrhagic strokes in a hypothetical Medicare AF population who were candidates for anticoagulation. The hypothetical AF population of 1,000 included 45% untreated, 10% on antiplatelet and 45% on anticoagulation therapy. AF prevalence, stroke risk (based on CHADS 2 ) and stroke risk-reduction were adjusted for age (≥ 65 yrs), comorbidities and anticoagulation/antiplatelet status. Annual incremental stroke-related healthcare costs were drawn from published literature and adjusted to 2010 US$. Results: The base case model estimated 132 ischemic strokes (21 fatal) and 49 hemorrhagic strokes (19 fatal) generating an estimated $12.25 million in stroke-related healthcare costs to Medicare. Keeping all other variables constant, a 10% increase in anticoagulant use from the untreated population would reduce ischemic stroke events by 12 (to 120; 19 fatal), hemorrhagic stroke events by 4 (to 44; 18 fatal), and stroke-related costs by more than $1 million. Conclusion: A 10% increase in anticoagulant use in a hypothetical AF cohort is expected to reduce stroke events, stroke-related fatalities and stroke-related costs by nearly 9%. Increased use of anticoagulation, with the potential to reduce the incidence of ischemic and hemorrhagic stroke, could significantly decrease stroke events, fatalities, and related healthcare costs.
27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor
Authors: Kim A. Papp, Mark G. Lebwohl, Leon Kircik, David Pariser, Bruce Strober, Gerald Krueger, David R. Berk, Lynn Navale, Robert C. Higham
Journal: Journal of the American Academy of Dermatology (2021)
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
Authors: Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, Andrea Gori, Miltiades Kyprianou, Peter Pickkers, Jesper Eugen-Olsen, Mario Clerici, Francisco Veas, Gilles Chatellier, Gilles Kaplanski, Mihai G Netea, Emanuele Pontali, Marco Gattorno, Raphael Cauchois, Emma Kooistra, Matthijs Kox, Alessandra Bandera, Hélène Beaussier, Davide Mangioni, Lorenzo Dagna, Jos W M van der Meer, Evangelos J Giamarellos-Bourboulis, Gilles Hayem, Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, Andrea Gori, Miltiades Kyprianou, Peter Pickkers, Jesper Eugen-Olsen, Mario Clerici, Francisco Veas, Gilles Chatellier, Gilles Kaplanski, Mihai G. Netea, Emanuele Pontali, Marco Gattorno, Raphael Cauchois, Emma Kooistra, Matthijs Kox, Alessandra Bandera, Hélène Beaussier, Davide Mangioni, Lorenzo Dagna, Jos W.M. van der Meer, Evangelos J. Giamarellos-Bourboulis, Gilles Hayem, Stefano Volpi, Maria Pia Sormani, Alessio Signori, Giorgio Bozzi, Francesca Minoia, Stefano Aliberti, Giacomo Grasselli, Laura Alagna, Andrea Lombardi, Riccardo Ungaro, Carlo Agostoni, Francesco Blasi, Giorgio Costantino, Anna Ludovica Fracanzani, Nicola Montano, Flora Peyvandi, Marcello Sottocorno, Antonio Muscatello, Giovanni Filocamo, Antonios Papadopoulos, Maria Mouktaroudi, Eleni Karakike, Maria Saridaki, Theologia Gkavogianni, Konstantina Katrini, Nikolaos Vechlidis, Christina Avgoustou, Stamatios Chalvatzis, Theodoros Marantos, Christina Damoulari, Georgia Damoraki, Sofia Ktena, Maria Tsilika, Panagiotis Koufargyris, Athanasios Karageorgos, Dionysia-Irene Droggiti, Aikaterini Koliakou, Garyfallia Poulakou, Konstantinos Tsiakos, Dimitra-Melia Myrodia, Areti Gravvani, Ioannis P. Trontzas, Konstantinos Syrigos, Ioannis Kalomenidis, Eleftheria Kranidioti, Periklis Panagopoulos, Vasileios Petrakis, Simeon Metallidis, Georgia Loli, Olga Tsachouridou, George N. Dalekos, Nikolaos Gatselis, Aggelos Stefos, Sarah Georgiadou, Vassiliki Lygoura, Haralampos Milionis, Maria Kosmidou, Ilias C. Papanikolaou, Karolina Akinosoglou, Efthymia Giannitsioti, Georgios Chrysos, Panagiotis Mavroudis, Chrysanthi Sidiropoulou, Georgios Adamis, Archontoula Fragkou, Aggeliki Rapti, Zoi Alexiou, Styliani Symbardi, Aikaterini Masgala, Konstantina Kostaki, Evangelos Kostis, Michael Samarkos, Petros Bakakos, Vassiliki Tzavara, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Vasileios Kotsis, George Tsoukalas, Ioannis Bliziotis, Michael Doumas, Aikaterini Argyraki, Ilias Kainis, Massimo Fantoni, Antonella Cingolani, Andrea Angheben, Chiara Simona Cardellino, Francesco Castelli, Francesco Saverio Serino, Emanuele Nicastri, Giuseppe Ippolito, Matteo Bassetti, Carlo Selmi
Journal: The Lancet Rheumatology (2021)
Integrity of Stent Polymer Layer after Drug-eluting Stent Implantation: In Vivo Comparison of Drug Eluting Stents
Authors: Watanabe Tetsuya, Fujita Masashi, Awata Masaki, Iida Osamu, Sera Fusako, Okamoto Shin, Tanaka Nobuaki, Ishihara Takayuki, Dohi Tomoharu, Mishima Tsuyoshi, Sato Kei, Nanto Kiyonori, Mizukami Yukika, Iida Takuma, Kanda Takashi, Shiraki Tatsuya, Ishida Yoshio, Uematsu Masaaki
Journal: Circulation (2012)
The continued need for animals to advance brain research
Authors: Judith R. Homberg, Roger A.H. Adan, Natalia Alenina, Antonis Asiminas, Michael Bader, Tom Beckers, Denovan P. Begg, Arjan Blokland, Marilise E. Burger, Gertjan van Dijk, Ulrich L.M. Eisel, Ype Elgersma, Bernhard Englitz, Antonio Fernandez-Ruiz, Carlos P. Fitzsimons, Anne-Marie van Dam, Peter Gass, Joanes Grandjean, Robbert Havekes, Marloes J.A.G. Henckens, Christiane Herden, Roelof A. Hut, Wendy Jarrett, Kate Jeffrey, Daniela Jezova, Andries Kalsbeek, Maarten Kamermans, Martien J. Kas, Nael Nadif Kasri, Amanda J. Kiliaan, Sharon M. Kolk, Aniko Korosi, S. Mechiel Korte, Tamas Kozicz, Steven A. Kushner, Kirk Leech, Klaus-Peter Lesch, Heidi Lesscher, Paul J. Lucassen, Anita Luthi, Liya Ma, Anne S. Mallien, Peter Meerlo, Jorge F. Mejias, Frank J. Meye, Anna S. Mitchell, Joram D. Mul, Umberto Olcese, Azahara Oliva González, Jocelien D.A. Olivier, Massimo Pasqualetti, Cyriel M.A. Pennartz, Piotr Popik, Jos Prickaerts, Liset M. de la Prida, Sidarta Ribeiro, Benno Roozendaal, Janine I. Rossato, Ali-Akbar Salari, Regien G. Schoemaker, August B. Smit, Louk J.M.J. Vanderschuren, Tomonori Takeuchi, Rixt van der Veen, Marten P. Smidt, Vladyslav V. Vyazovskiy, Maximilian Wiesmann, Corette J. Wierenga, Bella Williams, Ingo Willuhn, Markus Wöhr, Monique Wolvekamp, Eddy A. van der Zee, Lisa Genzel
Journal: Neuron (2021)
Risk factors profile of young and older patients with myocardial infarction
Authors: Marios Sagris, Alexios S Antonopoulos, Panagiotis Theofilis, Evangelos Oikonomou, Gerasimos Siasos, Sotirios Tsalamandris, Charalambos Antoniades, Emmanouil S Brilakis, Juan C Kaski, Dimitris Tousoulis
Journal: Cardiovascular Research (2021)

Myocardial infarction (MI) among young adults (<45 years) represents a considerable proportion of the total heart attack incidents. The underlying pathophysiologic characteristics, atherosclerotic plaque features, and risk factors profile differ between young and older patients with MI. This review article discusses the main differences between the younger and elderly MI patients as well as the different pathogenic mechanisms underlying the development of MI in the younger. Young patients with MI often have eccentric atherosclerotic plaques with inflammatory features but fewer lesions, and are more likely to be smokers, obese, and have poor lifestyle, such as inactivity and alcohol intake. Compared to older MI patients, younger are more likely to be men, have familial-combined hyperlipidaemia and increased levels of lipoprotein-a. In addition, MI in younger patients may be related to use of cannabis, cocaine use, and androgenic anabolic steroids. Genomic differences especially in the pathways of coagulation and lipid metabolism have also been identified between young and older patients with MI. Better understanding of the risk factors and the anatomic and pathophysiologic processes in young adults can improve MI prevention and treatment strategies in this patient group. Awareness could help identify young subjects at increased risk and guide primary prevention strategies. Additional studies focusing on gene pathways related to lipid metabolism, inflammation, and coagulation are needed.
The bile acid‐activated retinoic acid response in dendritic cells is involved in food allergen sensitization
Authors: Renlan Wu, Xiefang Yuan, Xingjie Li, Ning Ma, Hongyu Jiang, Hongmei Tang, Guofeng Xu, Zhigang Liu, Zongde Zhang
Journal: Allergy (2021)

Alteration of commensal microbiota is highly correlated with the prevalence of allergic reactions to food in the gastrointestinal tract. The mechanisms by which microbiota modulate food allergen sensitization in the mucosal site are not fully understood.We generate DCs specific knockout of retinoic acid receptor α (Rara) gene mice (DC KO Rara) to evaluate food sensitization. The bile acid-activated retinoic acid response was evaluated by flow cytometry, real-time RT-PCR and Illumina transcriptome sequencing. The global effect of Abx treatment on BA profiles in the mucosal lymph tissue mLN in mice was examined by UPLC-MS analysis.In this study, we demonstrate that depletion of commensal gut bacteria leads to enhanced retinoic acid (RA) signaling in mucosal dendritic cells (DCs). RA signaling in DCs is required for the production of food allergen-specific IgE and IgG1. Antibiotics induced an enlarged bile acid (BA) pool, and dysregulated BA profiles contributed to enhanced RA signaling in mucosal DCs. BA-activated RA signaling promoted DC upregulation of interferon I signature, RA signature, OX40L, and PDL2, which may lead to T helper 2 differentiation of CD4+ T cells. BA-activated RA signaling involved the farnesoid X receptor and RA receptor α (RARa) interaction. Depletion of bile acid reduces food allergen specific IgE and IgG1 levels in mice.Our research unveils a mechanism of food sensitization modulated by BA-RA signaling in DCs, which suggests a potential new approach for the intervention of food allergic reactions.
Iron distribution in different tissues of homozygous <scp>Mask</scp> (msk/msk) mice and the effects of oral iron treatments
Authors: Michela Asperti, Elisa Brilli, Andrea Denardo, Magdalena Gryzik, Francesca Pagani, Fabiana Busti, Germano Tarantino, Paolo Arosio, Domenico Girelli, Maura Poli
Journal: American Journal of Hematology (2021)

Abstract Iron‐refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by genetic mutations on TMPRSS6 gene which encodes Matriptase2 (MT2). An altered MT2 cannot appropriately suppress hepatic BMP6/SMAD signaling in case of low iron, hence hepcidin excess blocks dietary iron absorption, leading to a form of anemia resistant to oral iron supplementation. In this study, using the IRIDA mouse model Mask, we characterized homozygous (msk/msk) compared to asymptomatic heterozygous (msk/wt) mice, assessing the major parameters of iron status in different organs, at different ages in both sexes. The effect of carbonyl iron diet was analyzed as control iron supplementation being used for many studies in mice. It resulted effective in both anemic control and msk/msk mice, as expected, even if there is no information about its mechanism of absorption. Then, we mainly compared two forms of oral iron supplement, largely used for humans: ferrous sulfate and Sucrosomial iron. In anemic control mice, the two oral formulations corrected hemoglobin levels from 11.40 ± 0.60 to 15.38 ± 1.71 g/dl in 2–4 weeks. Interestingly, in msk/msk mice, ferrous sulfate did not increase hemoglobin likely due to ferroportin/hepcidin‐dependent absorption, whereas Sucrosomial iron increased it from 11.50 ± 0.60 to 13.53 ± 0.64 g/dl mainly in the first week followed by a minor increase at 4 weeks with a stable level of 13.30 ± 0.80 g/dl, probably because of alternative absorption. Thus, Sucrosomial iron, already used in other conditions of iron deficiency, may represent a promising option for oral iron supplementation in IRIDA patients.
Covid-19: Most symptomatic children recover within a week, study finds
Authors: Elisabeth Mahase
Journal: BMJ (2021)

Covid-19: Most symptomatic children recover within a week, study finds Elisabeth MahaseMost children who test positive for covid-19 and experience symptoms recover within a week, although a small proportion are unwell for more than four weeks, a study has found. 1 The data, taken from the Covid Symptom Study and analysed by researchers at King's College, London, included 1734 children (588 aged 5-11 and 1146 aged 12-17) who had a positive SARS-CoV-2 test result and calculable illness duration within the study timeframe (after 1 September 2020).The most reported symptoms were headache (62.2%) and fatigue (55.0%), and the median illness duration was six days.A total of 77 children (4.4%) experienced symptoms for at least 28 days, and this was more common in older children (5.1% in older v 3.1% in younger.)Twenty five children had symptoms for at least 56 days.The paper, published in the Lancet Child & Adolescent Health, found that in children who had symptoms for longer the symptom burden was said to be low after day 28 (median 2 symptoms).
Injectable self-healing hydrogel with siRNA delivery property for sustained STING silencing and enhanced therapy of intervertebral disc degeneration
Authors: Jiaxin Chen, Haifeng Zhu, Yutao Zhu, Chenchen Zhao, Shengyu Wang, Yixin Zheng, Ziang Xie, Yang Jin, Honghai Song, Linjun Yang, Jin Zhang, Jiayong Dai, Zhijun Hu, Huaiyu Wang
Journal: Bioactive Materials (2021)

Inflammatory responses of nucleus pulposus (NP) can induce imbalanced anabolism and catabolism of extracellular matrix, and the cytosolic dsDNA accumulation and STING-NF-κB pathway activation found in NP inflammation are considered as fairly important cause of intervertebral disc (IVD) degeneration. Herein, we constructed a siSTING delivery hydrogel of aldehyde hyaluronic acid (HA-CHO) and poly(amidoamine) PAMAM/siRNA complex to intervene the abnormal STING signal for IVD degeneration treatment, where the formation of dynamic Schiff base bonds in the system (siSTING@HPgel) was able to overcome the shortcomings such as low cellular uptake, short half-life, and rapid degradation of siRNA-based strategy. PAMAM not only formed complexes with siRNA to promote siRNA transfection, but also served as dynamic crosslinker to construct hydrogel, and the injectable and self-healing hydrogel efficiently and steadily silenced STING expression in NP cells. Finally, the siSTING@HPgel significantly eased IVD inflammation and slowed IVD degeneration by prolonging STING knockdown in puncture-induced IVD degeneration rat model, revealing that STING pathway was a therapeutic target for IVD degeneration and such novel hydrogel had great potential for being applied to many other diseases for gene delivery.
Key considerations on the development of biodegradable biomaterials for clinical translation of medical devices: With cartilage repair products as an example
Authors: Li Wang, Xiaolei Guo, Jiaqing Chen, Zhen Zhen, Bin Cao, Wenqian Wan, Yuandong Dou, Haobo Pan, Feng Xu, Zepu Zhang, Jianmei Wang, Daisong Li, Quanyi Guo, Qing Jiang, Yanan Du, Jiakuo Yu, Boon Chin Heng, Qianqian Han, Zigang Ge
Journal: Bioactive Materials (2021)

With the interdisciplinary convergence of biology, medicine and materials science, both research and clinical translation of biomaterials are progressing at a rapid pace. However, there is still a huge gap between applied basic research on biomaterials and their translational products - medical devices, where two significantly different perspectives and mindsets often work independently and non-synergistically, which in turn significantly increases financial costs and research effort. Although this gap is well-known and often criticized in the biopharmaceutical industry, it is gradually widening. In this article, we critically examine the developmental pipeline of biodegradable biomaterials and biomaterial-based medical device products. Then based on clinical needs, market analysis, and relevant regulations, some ideas are proposed to integrate the two different mindsets to guide applied basic research and translation of biomaterial-based products, from the material and technical perspectives. Cartilage repair substitutes are discussed here as an example. Hopefully, this will lay a strong foundation for biomaterial research and clinical translation, while reducing the amount of extra research effort and funding required due to the dissonance between innovative basic research and commercialization pipeline.
P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
Authors: J. Tabernero, J. Bendell, R. Corcoran, S. Kopetz, J. Lee, M. Davis, J. Christensen, A. Chi, T. Kheoh, R. Yaeger
Journal: Annals of Oncology (2021)
Contingency Management for Patients Receiving Medication for Opioid Use Disorder
Authors: Hypatia A. Bolívar, Elias M. Klemperer, Sulamunn R. M. Coleman, Michael DeSarno, Joan M. Skelly, Stephen T. Higgins
Journal: JAMA Psychiatry (2021)

Medication treatment for opioid use disorder (MOUD) is efficacious, but comorbid stimulant use and other behavioral health problems often undermine efficacy.To examine the association of contingency management, a behavioral intervention wherein patients receive material incentives contingent on objectively verified behavior change, with end-of-treatment outcomes for these comorbid behavioral problems.A systematic search of PubMed, Cochrane CENTRAL, Web of Science, and reference sections of articles from inception through May 5, 2020. The following search terms were used: vouchers OR contingency management OR financial incentives.Prospective experimental studies of monetary-based contingency management among participants receiving MOUD.Following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, 3 independent investigators extracted data from included studies for a random-effects meta-analysis.Primary outcome was the association of contingency management at end-of-treatment assessments with 6 clinical problems: stimulant use, polysubstance use, illicit opioid use, cigarette smoking, therapy attendance, and medication adherence. Random-effects meta-analysis models were used to compute weighted mean effect size estimates (Cohen d) and corresponding 95% CIs separately for each clinical problem and collapsing across the 3 categories assessing abstinence and the 2 assessing treatment adherence outcomes.The search identified 1443 reports of which 74 reports involving 10 444 unique adult participants met inclusion criteria for narrative review and 60 for inclusion in meta-analyses. Contingency management was associated with end-of-treatment outcomes for all 6 problems examined separately, with mean effect sizes for 4 of 6 in the medium-large range (stimulants, Cohen d = 0.70 [95% CI, 0.49-0.92]; cigarette use, Cohen d = 0.78 [95% CI, 0.43-1.14]; illicit opioid use, Cohen d = 0.58 [95% CI, 0.30-0.86]; medication adherence, Cohen d = 0.75 [95% CI, 0.30-1.21]), and 2 in the small-medium range (polysubstance use, Cohen d = 0.46 [95% CI, 0.30-0.62]; therapy attendance, d = 0.43 [95% CI, 0.22-0.65]). Collapsing across abstinence and adherence categories, contingency management was associated with medium effect sizes for abstinence (Cohen d = 0.58; 95% CI, 0.47-0.69) and treatment adherence (Cohen d = 0.62; 95% CI, 0.40-0.84) compared with controls.These results provide evidence supporting the use of contingency management in addressing key clinical problems among patients receiving MOUD, including the ongoing epidemic of comorbid psychomotor stimulant misuse. Policies facilitating integration of contingency management into community MOUD services are sorely needed.
27851 Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2
Authors: Alice B. Gottlieb, Joseph F. Merola, April W. Armstrong, Laura Savage, Soumya D. Chakravarty, Alexa P. Kollmeier, Bei Zhou, Ya-Wen Yang, Kristen Sweet, Wolf-Henning Boehncke
Journal: Journal of the American Academy of Dermatology (2021)
ホルモン耐性HER2陽性転移性乳癌(MBC)のインシュリン様成長因子1受容体(IGF-1R)発現とトラスツズマブ(T)単独療法の効果の関係
Authors: Shimizu C, Hasegawa T, Ando M, Fujiwara Y, Tani Y
Journal: Journal of Clinical Oncology (2004)
Editor's Note: Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles
Authors: Hee Dong Han, Lingegowda S. Mangala, Jeong Won Lee, Mian M.K. Shahzad, Hye Sun Kim, Deyu Shen, Eun Ji Nam, Edna M. Mora, Rebecca L. Stone, Chunhua Lu, Sun Joo Lee, Ju Won Roh, Alpa M. Nick, Gabriel Lopez-Berestein, Anil K. Sood
Journal: Clinical Cancer Research (2021)

The editors are publishing this note to alert readers to a concern about [this article][1] ([1][2]): in Supplementary Fig. S6B, one of the representative CD31 images was duplicated between the "FAK/CH-NP+Docetaxel" and "FAK/RGD-CH-NP+Docetaxel" groups. MD Anderson's Office of Research
Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control
Authors: Ian C. Miller, Ali Zamat, Lee-Kai Sun, Hathaichanok Phuengkham, Adrian M. Harris, Lena Gamboa, Jason Yang, John P. Murad, Saul J. Priceman, Gabriel A. Kwong
Journal: Nature Biomedical Engineering (2021)
治療後の肝細胞癌に対する最も顕著な予後因子であるレンズマメレクチンA反発性アルファフェトプロテイン(AFP-U)
Authors: Tanaka M, Saitoh A, Ito K, Kumada T, Oka H, Kasugai H, Seki T, Osaki Y, Kudo M, Satomura S
Journal: Hepatology (2000)